Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01273844|
Recruitment Status : Completed
First Posted : January 11, 2011
Last Update Posted : April 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Amyloidosis||Drug: Bortezomib||Not Applicable|
Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4. After two cycles of vel / dex therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks.Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 100,140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients ) and Vel 1mg/m2 (days -6, -3, +1, +4) will be given. Four additional 21-day cycles of Vel treatment (with a dose of 1.6mg/m2 on day 1 and 8 of the cycle) will be conducted as consolidation therapy during the recommended 60-90 days after HSCT, or after resumption of hematopoietic function ( neutrophil count > 1.5x109/L and platelet count> 50x109/L). Later patients won't need maintenance therapy.
The efficacy criteria are the international standards set with consensus of experts in the Tenth International Symposium on Amyloid and Amyloidosis.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Combination of Bortezomib and Dexamethasone Followed by HSCT in AL|
|Actual Study Start Date :||March 1, 2011|
|Actual Primary Completion Date :||May 12, 2016|
|Actual Study Completion Date :||May 12, 2016|
Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
Other Name: autologous hematopoietic stem cell transplantation
- Complete response rate [ Time Frame: 12 months ]Complete response rate at 12 months post-transplantation
- overall response rate [ Time Frame: 12 months ]overall response rate(ie.,CR + PR) at 12 months post-transplantation
- progression-free survival [ Time Frame: 2 years ]progression-free survival (PFS) at 2 years post-transplantation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273844
|Suzhou, Jiangsu, China, 215325|
|Principal Investigator:||zhihong Liu, Master||Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China|